(A) A schematic outline of the mouse model of EoE, ciprofloxacin administration, and BrdU labeling in the CC10–IL-13 double transgenic mice. DOX, doxycycline. (B) Representative H&E images of the distal murine esophagus (top and middle images) and IHC images of the eosinophilic infiltration (bottom images) in the control (Ctrl), CC10–IL-13 double transgenic mice (TG), and CC10–IL-13 double transgenic mice treated with ciprofloxacin (TG + CIPRO). Scale bars: 100 μm (top and bottom images) and 50 μm (middle images). (C) Quantification of the epithelial thickness, intercellular spaces, and eosinophil infiltration in the esophagus as box-and-whisker plot. The box represents the 50th percentile of the data, whiskers show minimum and maximum values, and the line in the box represents the median. Each marker represents an individual measurement (see Methods). (D) Representative immunofluorescence images of the murine esophageal epithelium in the control, CC10–IL-13 double transgenic mice (TG), and CC10–IL-13 double transgenic mice treated with ciprofloxacin (TG + CIPRO). Scale bar: 50 μm. (E) Quantification of MCM2-positive cells in the esophageal epithelium as mean ± SEM. Each marker represents an individual section of the proximal and distal esophagus from 3 mice. (F) The fraction of actively proliferating BrdU-positive cells in the epithelium of the murine esophagus was determined by flow cytometry, normalized to the control mice, and is presented as mean ± SEM. Each marker represents an individual mouse. (G) Quantification of the esophageal epithelial cells in the phases of the cell cycle by flow cytometry as mean ± SEM. Each marker represents an individual mouse. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 1 way ANOVA with Holm-Šidák correction (C, E, and F) or 2-way ANOVA with FDR correction by Benjamini, Krieger, and Yekutieli (G). NS, not significant.